<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01480843</url>
  </required_header>
  <id_info>
    <org_study_id>2011-05</org_study_id>
    <nct_id>NCT01480843</nct_id>
  </id_info>
  <brief_title>Simplified Insulin Protocol Using Lantus in Elderly</brief_title>
  <acronym>SIMPLE</acronym>
  <official_title>Simplification of Diabetes Regimen in Elderly Patients Using Glargine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joslin Diabetes Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Joslin Diabetes Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out if simplifying your diabetes treatment by decreasing
      number of insulin injections, with the help of a long acting insulin called glargine, can
      decrease the episodes of low blood glucose.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As patients with diabetes age, adverse social and medical problems may arise. Because of
      these problems patients, even those managing their diabetes for many years, find it difficult
      to continue with complicated insulin schedules. This may lead to errors in treatment and poor
      glucose control. Simplification of treatment has been found to the decrease risk of low blood
      glucose, a very dangerous condition at this age. In a previous study, the investigators found
      that simplifying treatment did not cause the blood sugars to rise out of control. In this
      study, the investigators plan to simplify insulin treatment and monitor for low glucose
      episodes with help of a continuous glucose monitor and A1C (measure of average glucose
      control over 3 months). The investigators will simplify the treatment by adding glucose
      lowering medications that you can take by mouth, in addition to the injection of long acting
      insulin called glargine.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Duration of Hypoglycemia Episodes</measure>
    <time_frame>baseline, 5 months, 8 months</time_frame>
    <description>duration of hypoglycemia measured by continuous glucose monitoring</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Frequency of Hypoglycemia Episodes From Baseline, 5 Months, 8 Months</measure>
    <time_frame>baseline, 5 months, 8 months</time_frame>
    <description>frequency of hypoglycemia episodes measured by continuous glucose monitoring per 5 days of continuous glucose monitoring data</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Glargine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>We plan to add long acting insulin glargine with/without oral medications to the regimen in all patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glargine</intervention_name>
    <description>Use of glargine with/without other glucose lowering agent to simplify insulin regimen in older adults</description>
    <arm_group_label>Glargine</arm_group_label>
    <other_name>Lantus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 70 years or older

          -  Diagnosis of diabetes mellitus Type II

          -  At least 2 (short-acting or mixed) insulin injections per day

          -  At least 1 episode of hypoglycemia (glucose value &lt;70) on screening CGM

        Exclusion Criteria:

          -  Patients with the following illnesses in the past 12 months Myocardial infarction
             Angina Coronary artery bypass grafting Percutaneous transluminal coronary angiography
             Cerebrovascular event (stroke, TIA)

          -  Active liver disease (history of cirrhosis or LFT &gt; 3 times normal)

          -  On dialysis or with severe renal dysfunction (creatinine clearance &lt;20 ml/min)

          -  Malignancy that limits life span to less than 18 months

          -  Patients seen in the geriatric clinic who already have simplified regimen as proposed
             in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medha N Munshi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Joslin Diabetes Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Joslin Diabetes Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Narayan KM, Boyle JP, Geiss LS, Saaddine JB, Thompson TJ. Impact of recent increase in incidence on future diabetes burden: U.S., 2005-2050. Diabetes Care. 2006 Sep;29(9):2114-6.</citation>
    <PMID>16936162</PMID>
  </reference>
  <reference>
    <citation>Economic consequences of diabetes mellitus in the U.S. in 1997. American Diabetes Association. Diabetes Care. 1998 Feb;21(2):296-309.</citation>
    <PMID>9539999</PMID>
  </reference>
  <reference>
    <citation>Bertoni AG, Kirk JK, Goff DC Jr, Wagenknecht LE. Excess mortality related to diabetes mellitus in elderly Medicare beneficiaries. Ann Epidemiol. 2004 May;14(5):362-7.</citation>
    <PMID>15177276</PMID>
  </reference>
  <reference>
    <citation>Blaum CS, Ofstedal MB, Langa KM, Wray LA. Functional status and health outcomes in older americans with diabetes mellitus. J Am Geriatr Soc. 2003 Jun;51(6):745-53.</citation>
    <PMID>12757559</PMID>
  </reference>
  <reference>
    <citation>Bonsignore P DL, Suhl E, Sternthal A, Giusti J, Munshi MN. Unrecognized Errors in Insulin Injection Techniques Are Frequent in Older Adults Even with Longer Duration of Insulin Use. In: American Diabetes Association annual meeting 2009; 2009; New Orleans LA; 2009. p. 913-P.</citation>
  </reference>
  <reference>
    <citation>Medha N. Munshi EB, Ramachandiran Cooppan. Diabetes in the Older Adult. In: Richard S. Beaser MatSoJDC, ed. Joslin's Diabetes Deskbook : A guide for primary care providers. 2nd ed. Boston: Joslin Diabetes Center; 2007:623-38.</citation>
  </reference>
  <reference>
    <citation>Shorr RI, Ray WA, Daugherty JR, Griffin MR. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. Arch Intern Med. 1997 Aug 11-25;157(15):1681-6.</citation>
    <PMID>9250229</PMID>
  </reference>
  <reference>
    <citation>McAulay V FB. Hypoglycemia in diabetes in old age. In: Sinclair A, Finucane P, ed. 2nd ed. Chichester, UK: John wiley and sons; 2001:133-52.</citation>
  </reference>
  <reference>
    <citation>Desouza C, Salazar H, Cheong B, Murgo J, Fonseca V. Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring. Diabetes Care. 2003 May;26(5):1485-9.</citation>
    <PMID>12716809</PMID>
  </reference>
  <reference>
    <citation>Frier BM. Hypoglycaemic valleys: an under-recognised problem in type 2 diabetes? Int J Clin Pract Suppl. 2002 Jul;(129):12-9. Review.</citation>
    <PMID>12166599</PMID>
  </reference>
  <reference>
    <citation>Zammitt NN, Frier BM. Hypoglycemia in type 2 diabetes: pathophysiology, frequency, and effects of different treatment modalities. Diabetes Care. 2005 Dec;28(12):2948-61. Review.</citation>
    <PMID>16306561</PMID>
  </reference>
  <reference>
    <citation>Ayres D SE, Capelson R, Weinger K, Munshi M. Identifying Barriers to Diabetes Education and Self-Care in Older Adults. In: American diabetes Association 65th scientific sessions 2005; San Diego CA; 2005. p. 941-P</citation>
  </reference>
  <reference>
    <citation>Munshi M, Grande L, Hayes M, Ayres D, Suhl E, Capelson R, Lin S, Milberg W, Weinger K. Cognitive dysfunction is associated with poor diabetes control in older adults. Diabetes Care. 2006 Aug;29(8):1794-9.</citation>
    <PMID>16873782</PMID>
  </reference>
  <reference>
    <citation>Munshi MN DL, Iwata I, Suhl E, Giusti J, Bonsignore P, Sternthal A The Risk of Hypoglycemia Is a Treatment-Limiting Factor in Older Adults Even with Poor Glycemic Control. In: American Diabetes Association annual meeting 2009; 2009; New Orleans LA; 2009. p. 2123-PO.</citation>
  </reference>
  <reference>
    <citation>Munshi MN, Hayes M, Sternthal A, Ayres D. Use of serum c-peptide level to simplify diabetes treatment regimens in older adults. Am J Med. 2009 Apr;122(4):395-7. doi: 10.1016/j.amjmed.2008.12.008.</citation>
    <PMID>19332236</PMID>
  </reference>
  <reference>
    <citation>Kovatchev BP, Clarke WL, Breton M, Brayman K, McCall A. Quantifying temporal glucose variability in diabetes via continuous glucose monitoring: mathematical methods and clinical application. Diabetes Technol Ther. 2005 Dec;7(6):849-62.</citation>
    <PMID>16386091</PMID>
  </reference>
  <reference>
    <citation>Hendriksen C, Faber OK, Drejer J, Binder C. Prevalence of residual B-cell function in insulin-treated diabetics evaluated by the plasma C-etide response to intravenous glucagon. Diabetologia. 1977 Dec;13(6):615-9.</citation>
    <PMID>338408</PMID>
  </reference>
  <reference>
    <citation>Faber OK, Binder C. C-peptide response to glucagon. A test for the residual beta-cell function in diabetes mellitus. Diabetes. 1977 Jul;26(7):605-10.</citation>
    <PMID>326604</PMID>
  </reference>
  <reference>
    <citation>Montorio I, Izal M. The Geriatric Depression Scale: a review of its development and utility. Int Psychogeriatr. 1996 Spring;8(1):103-12. Review.</citation>
    <PMID>8805091</PMID>
  </reference>
  <reference>
    <citation>Arbuthnott K, Frank J. Trail making test, part B as a measure of executive control: validation using a set-switching paradigm. J Clin Exp Neuropsychol. 2000 Aug;22(4):518-28.</citation>
    <PMID>10923061</PMID>
  </reference>
  <reference>
    <citation>Welch G, Weinger K, Anderson B, Polonsky WH. Responsiveness of the Problem Areas In Diabetes (PAID) questionnaire. Diabet Med. 2003 Jan;20(1):69-72. Review.</citation>
    <PMID>12519323</PMID>
  </reference>
  <reference>
    <citation>Polonsky WH, Anderson BJ, Lohrer PA, Welch G, Jacobson AM, Aponte JE, Schwartz CE. Assessment of diabetes-related distress. Diabetes Care. 1995 Jun;18(6):754-60.</citation>
    <PMID>7555499</PMID>
  </reference>
  <reference>
    <citation>Jacobson AM, de Groot M, Samson JA. The evaluation of two measures of quality of life in patients with type I and type II diabetes. Diabetes Care. 1994 Apr;17(4):267-74.</citation>
    <PMID>8026281</PMID>
  </reference>
  <reference>
    <citation>Weinger K, Butler HA, Welch GW, La Greca AM. Measuring diabetes self-care: a psychometric analysis of the Self-Care Inventory-Revised with adults. Diabetes Care. 2005 Jun;28(6):1346-52.</citation>
    <PMID>15920050</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2011</study_first_submitted>
  <study_first_submitted_qc>November 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2011</study_first_posted>
  <results_first_submitted>April 25, 2017</results_first_submitted>
  <results_first_submitted_qc>October 9, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">November 8, 2017</results_first_posted>
  <last_update_submitted>October 9, 2017</last_update_submitted>
  <last_update_submitted_qc>October 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>simplification</keyword>
  <keyword>glargine</keyword>
  <keyword>elderly</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Glargine</title>
          <description>We plan to add long acting insulin glargine with/without oral medications to the regimen in all patients.
Glargine: Use of glargine with/without other glucose lowering agent to simplify insulin regimen in older adults</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Glargine</title>
          <description>We plan to add long acting insulin glargine with/without oral medications to the regimen in all patients.
Glargine: Use of glargine with/without other glucose lowering agent to simplify insulin regimen in older adults</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="65"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Duration of Hypoglycemia Episodes</title>
        <description>duration of hypoglycemia measured by continuous glucose monitoring</description>
        <time_frame>baseline, 5 months, 8 months</time_frame>
        <population>Subject drop outs</population>
        <group_list>
          <group group_id="O1">
            <title>Glargine</title>
            <description>We plan to add long acting insulin glargine with/without oral medications to the regimen in all patients.
Glargine: Use of glargine with/without other glucose lowering agent to simplify insulin regimen in older adults</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Duration of Hypoglycemia Episodes</title>
          <description>duration of hypoglycemia measured by continuous glucose monitoring</description>
          <population>Subject drop outs</population>
          <units>minutes of hypoglycemia</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="277" spread="252"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111" spread="184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 months</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" spread="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Frequency of Hypoglycemia Episodes From Baseline, 5 Months, 8 Months</title>
        <description>frequency of hypoglycemia episodes measured by continuous glucose monitoring per 5 days of continuous glucose monitoring data</description>
        <time_frame>baseline, 5 months, 8 months</time_frame>
        <population>Subject drop outs</population>
        <group_list>
          <group group_id="O1">
            <title>Glargine</title>
            <description>We plan to add long acting insulin glargine with/without oral medications to the regimen in all patients.
Glargine: Use of glargine with/without other glucose lowering agent to simplify insulin regimen in older adults</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Frequency of Hypoglycemia Episodes From Baseline, 5 Months, 8 Months</title>
          <description>frequency of hypoglycemia episodes measured by continuous glucose monitoring per 5 days of continuous glucose monitoring data</description>
          <population>Subject drop outs</population>
          <units>episodes of hypoglycemia</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Event data was collected during the 8 month time period that the participants were in the trail.</time_frame>
      <desc>Participants were contacted ona weekly or bi-weekly basis to discuss blood glucose readings and an other issues that they had been having.</desc>
      <group_list>
        <group group_id="E1">
          <title>Glargine</title>
          <description>We plan to add long acting insulin glargine with/without oral medications to the regimen in all patients.
Glargine: Use of glargine with/without other glucose lowering agent to simplify insulin regimen in older adults</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac stent placed</sub_title>
                <description>Subject hospitalized for cardiac stent placement. Unrelated to study intervention.</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bowel Obstruction</sub_title>
                <description>Subject hospitalized for bowel obstruction.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>Subject passed away from unknown causes</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Hospitalization for gout</sub_title>
                <description>subject hospitalized for gout flare up, unrelated to study intervention.</description>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Hospitalization for internal bleeding</sub_title>
                <description>Subject hospitalized due to internal bleeding from mediation unrelated to study intervention.</description>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Hospitalization due to fall</sub_title>
                <description>Subject tripped and fell, resulting in hospitalization. Unrelated to study procedures.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Hospitalization for Cellulitis</sub_title>
                <description>subject hospitalized for cellulitis unrelated to study intervention.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization for Acute renal failure</sub_title>
                <description>hospitalization for acute on chronic renal failure, thought to be interstitial nephritis. Unrelated to study intervention</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>hysterectomy</sub_title>
                <description>subject hospitalized for hysterectomy</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Stroke</sub_title>
                <description>2 subjects had strokes and subsequent hospitalization, unrelated to study intervention.</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Prednisone Taper Needed</sub_title>
                <description>Subjects paused their time in the study due to the use of prednisone, unrelated to study intervention. Prednisone affected blood glucose readings during this time.</description>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medha Munshi, MD</name_or_title>
      <organization>Joslin Diabetes Center</organization>
      <phone>617-309-4683</phone>
      <email>medha.munshi@joslin.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

